LP
KALV

LMR Partners’s KalVista Pharmaceuticals KALV Stock Holding History

LMR Partners’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,000
Closed -$306K – 1237
2023
Q4 		$306K Hold
25,000
– – ﹤0.01% 697
2023
Q3 		$241K Buy
+25,000
New +$255K ﹤0.01% 623

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

LMR Partners's KALV Position: Q2 2021 in Review

LMR Partners sold out of KalVista Pharmaceuticals (KALV) in Q2 2021, closing a stake of 25,000 shares — an estimated $642K sold.

LMR Partners first reported a position in KALV in Q1 2021 and held it in 1 quarter. The position peaked at $642K in Q1 2021. 110 funds tracked by Wall St. Rank hold KALV as of Q2 2021.

  • LMR Partners reported no remaining KalVista Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • LMR Partners sold 25,000 KalVista Pharmaceuticals shares in Q2 2021, an estimated $642K.
  • LMR Partners first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • LMR Partners's KalVista Pharmaceuticals position peaked at $642K in Q1 2021.
  • 110 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2021.

Based on LMR Partners's 13F filing for Q2 2021, filed 16 Aug 2021.